Index

Aging and lid, 166
Anesthesia for blepharoplasty, 48
Anomalies of lid, 165–166
Anophthalmia, 11–21
  congenital, total, 11–13
  conjunctiva and, 16–18
  cul-de-sac reconstruction in, 14–15
    sutures for, 14
  ectropion complicating, 18–19
  entropion complicating, 18–19
  implants in
    extrusive, 19–20
    gold ball, 13
  mold in, 16–18
  ptosis and, 20–21
  skin graft in, 16–18
  socket of
    contracted, 15–16
    gold ball implanted into, 13
    small, 12
    surgical, scar resection for symblepharon in, 15
  trichiasis complicating, 18–19

Baggy lids, 47–53, 166
Ball implanted into socket of anophthalmia, 13
Beard modification of Fasanella-Servat operation, 124–125
Bell's phenomenon in blepharoptosis, 102
Bick procedure in senile ectropion, 35, 36
Biopsy technique in orbital region tumors, 4–5
Blepharochalasis, 47, 166
Blepharophimosis syndrome, 104
  surgery, 111
Blepharoplasty, 47
  anesthesia for, 48
  complications of, 52
  in middle and older age patients, 51–52
  procedure, 48–52
  in young patients, 48–51
Blepharoptosis, 97–115. *See also* Ptosis
  Bell's phenomenon in, 102
  brow suspension in, 106–107
  clinical evaluation, 97–104
  edrophonium test in, 102
  examination in, 98
  excess eyelid skin in, 101
  history, 97
  levator function in, 99–100
  levator resection in, 105–106
  lid margin position in, 100–101
  measurements in, 98–103
  observation of, 97–98
  photographs in, 102–103
  rectus suspension in, superior, 107
  therapy, 105–114
Blepharotomy, transverse, in entropion, 65–67
Brow suspension in blepharoptosis, 106–107
Bullous keratopathy, contact lenses in, 136–137
Burns, 55–69
  early treatment of, 57
  examination in, 55–57

Callahan modification of Fasanella-Servat operation, 126

Canaliculus lacerations, 60–62
Canthus
  tendon lacerations, 62–63
  tumors, 7–8
Cautery
  blepharoplasty and, 49
  Ziegler, in senile entropion, 37–38
Chemical injuries
  hospital therapy of, 58
  surgery of, 64–69
Cicatricial ectropion. *See* Ectropion, cicatricial
Cicatricial entropion. *See* Entropion, cicatricial
Cicatrizing diseases of lids, 41–44, 64–65
Conjunctiva
  anophthalmia surgery and, 16–18
  contact lenses in keratoconjunctival desiccation, 138
  office evaluation for plastic surgery, 166
  tumors, 166
Contact lenses, therapeutic, 131–141
  in corneal exposure, 138–139
  as cosmetic cover shells, 139–140
  in fornices expansion, 138
  indications for, 136–140
  in keratitis, neurotrophic, 139
  in keratoconjunctival desiccation, 138
  in keratopathy, bullous, 136-137
  in lid deformities, 139
  materials for, 131–132
  method for, 131–132
  molding technique, 132–136
  as surgical splints, 138
  in symblepharon surgery, 137–138
Cornea
  exposure, contact lenses in, 138–139
  office evaluation for plastic surgery, 166
  symblepharon adherent to, 68–69
Cosmetic cover shells, contact lenses as, 139–140
Cosmetic deformities, office evaluation for plastic surgery, 169–170
Cuenod-Natiff procedure, modified, in entropion, 65–67
Cul-de-sac reconstruction in anophthalmia, 14–15
  sutures for, 14
Cyclotropia and fractures, 156–157

Decompression in exophthalmos, 79–82, 92–93
Degenerative, discussion of term, 162
Dermochalasis, 47–48
Diplopia in motility problems, 91
Dye studies in epiphora, 29–30

Ectropion
  cicatricial, 41, 42
    preoperative severe, 64–65
  complicating
    anophthalmia, 18–19
    blepharoplasty, 52
  senile, 34–37
    Bick procedure in, 35, 36
    everted punctum repair in, 36–37
    lid closure by figure-of-eight suture, 34–35
    lid margin closure, direct, 34–35
Edrophonium test in blepharoptosis, 102
Elevator weakness complicating ptosis, 111
Endocrine exophthalmos. *See* Exophthalmos, endocrine
Endocrine ophthalmopathy. *See* Ophthalmopathy, endocrine
Enophthalmos, 167, 168
Entropion
  blepharotomy for, transverse, 65–67
  cicatricial, 41–44
    basic surgical concepts, 42–43
    tarsal graft in, 42–44
      mucous membrane for, 43–44
    trichiasis and, 42
  complicating anophthalmia, 18–19

modified Cuenod-Natiff procedure in, 65–67
senile, 37–40
Kwitko operation in, 38–39
Wheeler lateral orbicularis transplantation in, 39–40
Wheeler orbicularis imbrication operation in, 38
Ziegler cautery in, 37–38
Epiblepharon, 47
Epinephrine for blepharoplasty, 48
Epiphora, 23–32
adult patients
dye studies in, 29–30
general investigation, 28–29
irrigation in, 29
probing in, 29
radiography in, 30
in infants, 26–27
probing in, 27
surgical procedures in, general comments, 30–32
Examination in office evaluation for plastic surgery, 162–170
Exenteration, orbital, 8
Exophthalmometer, Hertel, 75, 163
Exophthalmos
definition, 167
endocrine, 71–84, 92–93
background, 71–73
decompression, 79–82, 92–93
diagnosis, 76
discussion of term, 73
evaluation, 74–76
Naffziger procedure in, 92
ocular complications, 76–79
orbitotomy in, lateral, 93
pathogenesis, 71–73
Sewell procedure in, 92–93
surgery
complications of, 83
contraindications, 82
indications for, 76–79
technique, 79–82
Walsh and Ogura procedure in, 93
pituitary
discussion of term, 73
thyrotoxicosis and, 72–73
Eyebrow suspension in blepharoptosis, 106–107
Eyelid. *See* Lid

Fasanella-Servat operation, 117–130
Beard modification, 124–125
Callahan modification, 126
discussion and comments, 127–129
indications for, ten listed by Beard, 117–118
procedure, detailed, 118–127
in ptosis, 110
sutures for, 122–123
Frost, 127
Fascia for brow suspension in blepharoptosis, 106–107
Figure-of-eight suture for lid closure, 34–35
Flap, skin–muscle, in blepharoplasty, 49–50
Forceps for blepharoplasty, 48
Fornices expansion, contact lenses in, 138
Fractures
cyclotropia and, 156–157
medial wall, 155, 158
nasoethmoid, 155–156
nasomaxillary, 155–156
orbit. *See* Orbit, fractures
Frost sutures in Fasanella-Servat operation, 127
Fundus examination, 163–164

Gold ball implanted into socket of anophthalmia, 13
Graft
flap, skin–muscle, in blepharoplasty, 49–50
skin, and anophthalmia, 16–18
tarsal, in cicatricial entropion, 42–44
mucous membrane for, 43–44

Hemangioma causing ptosis, 113
Hematoma complicating blepharoplasty, 52

Henderson procedure in lid retraction, 88–89
Hertel exophthalmometer, 75, 163
Hildreth cautery for blepharoplasty, 49
Hormones in endocrine exophthalmos, 72
Hospital therapy for burns and trauma, 58
Hypersecretion, 23–24
Hypertelorism, examination for, 163
Hyposecretion, 24
Hypotropia causing pseudoptosis, 114

Iliff forceps for blepharoplasty, 48
Implants
  in anophthalmia
    extrusive, 19-20
    gold ball, 13
  methyacrylate, in orbital fracture repair, 143–144
Infant, epiphora of, 26–27
  probing in, 27
Injuries. *See* Trauma
Irrigation in epiphora, 29

Jaw-winking ptosis, 104
  surgery of, 111, 112

Keratitis
  neuroparalytic, 24
  neurotrophic, contact lenses in, 139
Keratoconjunctival desiccation, contact lenses in, 138
Keratoconjunctivitis sicca, 24
Keratopathy, bullous, contact lenses in, 136–137
Kwitko operation in senile entropion, 38–39

Lacerations
  canaliculus, 60–62
  canthal tendon, 62–63
  hospital therapy, 58
  lid margin, 59–60
  surgery of, 58–63
Lacrimal system
  disorders, 23–32
  office evaluation for plastic surgery, 168–169
Laxity, tissue, discussion of term, 162
Lenses. *See* Contact lenses
Levator
  function
    in blepharoptosis, 99–100
    definition, 110
  recession in lid retraction, 87
  resection
    in blepharoptosis, 105–106
    Fasanella-Servat operation. *See* Fasanella-Servat operation
    maximum, definition, 110
    moderate, definition, 110
    small, definition, 110
Lid
  aging and, 166
  anomalies, 165–166
    contact lenses in, 139
    large, 6–7
  baggy, 47–53, 166
  cicatrizing diseases of, 41–44, 64–65
  closure by figure-of-eight suture, 34–35
  defects and deformities. *See* Lid, anomalies *above*
  excess skin in blepharoptosis, 101
  margin
    direct closure of, 34–35
    examination of, 163
    lacerations, 59–60
    position in blepharoptosis, 100–101
    tumors, 5–6
  office evaluation for plastic surgery, 165–166
  retraction, 86–89
    Henderson procedure in, 88–89
    levator recession in, 87
    Moran procedure in, 87–88
  senile changes, 33–34
  trauma, 165
  tumors, 165

free lid margin, 5–6
radiation vs. surgical treatment of, 9–10
upper, paralysis, palpebral spring for, 145–151
Lidocaine for blepharoplasty, 48

Marcus Gunn jaw-winking ptosis, 104
surgery, 111, 112
Maturity, discussion of term, 162
Medial wall fractures, 155, 158
Methyacrylate implants in orbital fracture repair, 143–144
Microphthalmia, 11–13
Mold in anophthalmia surgery, 16–18
Molding technique for therapeutic contact lenses, 132–136
Moran procedure in lid retraction, 87–88
Motility problems, 89–91
pathological changes in muscles, 90
surgical intervention, 91
Mucous membrane for tarsal graft in cicatricial entropion, 43–44
Muscle
extraocular, measurements of, 163
ocular, complications of orbital fracture, 153–160
pathological changes in motility problems, 90
skin–muscle flap in blepharoplasty, 49–50
slips in brow suspension in blepharoptosis, 106
Myogenic ptosis, 111-112

Naffziger procedure in endocrine exophthalmos, 92
Nasoethmoid fractures, 155–156
Nasomaxillary fractures, 155–156
Needle, Tenzel canaliculus, 61
Neurofibroma causing ptosis, 113
Neurogenic ptosis, 111
Neuroparalytic keratitis, 24
Neurophthalmological examination, 164
Neurotrophic keratitis, contact lenses in, 139

Ocular muscle complications of orbital fractures, 153–160
Office evaluation for plastic surgery, 161-170
Ophthalmopathy, endocrine, 85–95
exophthalmos. *See* Exophthalmos, endocrine
lid retraction, 86–89
management, considerations in, 85–86
motility problems, 89–91
Ophthalmoplegia ptosis, 112
Orbit
exenteration, 8
fractures
diagnosis, 153–154
inferior, 156–157
lateral, 155
management
early, 157–158
late, 158–159
ocular muscle complications, 153–160
repair, methyacrylate implants for, 143–144
superior, 155
office evaluation for plastic surgery, 167-168
proptosis, 167
tumors, 167–168
Orbital region tumors, 3–10
Orbitotomy, lateral, in endocrine exophthalmos, 93

Palpebral spring in upper eyelid paralysis, 145–151
Paralysis, upper eyelid, palpebral spring for, 145–151
Phantom tumors, 8–9
Photographs in blepharoptosis, 102–103
Pituitary exophthalmos
discussion of term, 73
thyrotoxicosis and, 72–73

Plastic surgery, office evaluation for, 161–170
Probing in epiphora
  adult patients, 29
  in infant, 27
Proptosis
  orbital, 167
  study of, 74
Pseudoptosis, 104
  hypotropia causing, 114
  surgery, 113–114
Pseudotumors, 168
Ptosis. *See also* Blepharoptosis
  acquired, 104
    edrophonium test in, 102
    lid margin position in, 100–101, 102
    surgery, 111–113
  anophthalmia and, 20–21
  classification, 103–104
  complicating blepharoplasty, 52
  congenital, 103–104
    elevator weakness complicating, 111
    lid lag on downward gaze, 100–101
    surgery of, 108–110
  definition, 99
  Fasanella-Servat operation in. *See* Fasanella-Servat operation
  hemangioma causing, 113
  Marcus Gunn jaw-winking, 104
    surgery, 111–112
  mechanical, 113
  myogenic, 111-112
  neurofibroma causing, 113
  neurogenic, 111
  ophthalmoplegia, 112
  senile, 112
  traumatic, 112–113
Punctum, everted, repair in senile ectropion, 36–37

Radiation and Radiography. *See under* Roentgenography
Rectus, superior, suspension in blepharoptosis, 107
Retroseptal tumors, transmarginal exposure, 9
Roentgenography
  diagnostic, 164
    epiphora, 30
  lid tumors, 9–10

Scar resection for symblepharon in surgical anophthalmia, 15
Scheie cautery for blepharoplasty, 49
Sclera for collagen in brow suspension in blepharoptosis, 106–107
Senile
  discussion of term, 162
  lid changes, 33–34. *See also* Ectropion, senile; Entropion, senile
  ptosis, 112
Sewell procedure in endocrine exophthalmos, 92–93
Skin
  graft, and anophthalmia, 16–18
  –muscle flap in blepharoplasty, 49–50
  slips in brow suspension in blepharoptosis, 106
Slit lamp examination, 163
Socket of anophthalmia. *See* Anophthalmia, socket of
Splints, surgical, contact lenses as, 138
Spring, palpebral, in upper eyelid paralysis, 145–151
Surgical splints, contact lenses as, 138
Sutures
  in canaliculus lacerations, 61–62
  in cul-de-sac reconstruction, 14
  in Fasanella-Servat operation, 122–123
    Frost, 127
  figure-of-eight, for lid closure, 34–35
  nonabsorbable, in brow suspension in blepharoptosis, 106
  traction, in lid lacerations, 60

Symblepharon
adherent to cornea, 68–69
knife edge, 65, 68
scar resection, in surgical anophthalmia, 15
surgery, contact lenses in, 137–138

Tarsal graft in cicatricial entropion, 42–44
mucous membrane for, 43–44
Tear drainage, obstruction to, 24–26
Tensilon test in blepharoptosis, 102
Tenzel canaliculus needle, 61
Thyrotoxicosis and pituitary exophthalmos, 72–73
Tissue laxity, discussion of term, 162
Tonometry, 164
Traction sutures for lid lacerations, 60
Trauma, 55–69
chemical
hospital therapy of, 58
surgery of, 64–69
early treatment of, 57
examination in, 55–57
lid, 165
ptosis due to, 112–113
Trichiasis
cicatricial entropion and, 42
complicating anophthalmia, 18–19
Tumors
canthi, 7–8
conjunctiva, 166
lid, 165
free lid margin, 5–6
radiation vs. surgical treatment, 9–10
orbit, 167–168
orbital region, 3–10
phantom, 8–9
retroseptal, transmarginal exposure, 9

Walsh and Ogura procedure, 79–80, 93
Wheeler operation in senile entropion
lateral orbicularis transplantation, 39–40
orbicularis imbrication operation, 38

X-ray. *See* Roentgenography

Ziegler cautery in senile entropion, 37–38
Z-plasty in knife edge symblepharon, 68

Index

Acetylcholine. *See* Miochol
Acetylcysteine, 235
Acrylic hydrogels, 238
Adapt, 235, 380
Adenosine arabinose, 404
Age
  of donor. *See* Donor, age of
  and pemphigus, 228
  and graft results, 348–360
  and use of alpha-chymotrypsin, 414
Aging, goblet cells in, 241
Air bubble, removal of, 286–287
Air in pupil dilation, 375
Alcohol, polyvinyl, 235
Allograft reaction, 188
Alpha-chymotrypsin, 211, 413–414
Ambulation, early, 368, 411–412
A-mode technique in ultrasound, 253
Amoils unit, 393, 415
Amphotericin B, 196
Anesthesia, 273–274, 340, 342, 365, 369
Anisometropia, 261–262
Ankyloblepharon in pemphigus, 228, 229
Anterior chamber, deepening of, 287–288
Antibiotics, 284, 380
Antifungal agents, 404
Antimetabolites, 191
Aphakia, subtotal vitrectomy, 302
Aphakic grafts, 212, 284–289, 354–360
  pressure in, 394, 395, 397
Arcus senilis, 408–409, 411
Arthritis in Sjögren's syndrome, 223
Astigmatism
  in contact lens fitting, 198
  in penetrating graft, 351
  postoperative, 419–420
  and use of keratometer, 302
Atraumatic surgery, 347, 371–373
Autografts, 188
Autokeratome, 264, 266–270
  vs. penetrating keratoplasty, 263
Autoophthalmoscopy, 197
Avitaminosis A, 230–231

Bacterial infection
  in avitaminosis A, 231
  secondary, in Stevens-Johnson syndrome, 226
Bacteriology in eye bank storage, 316
Bandage lens. *See* Contact lens, soft
Beveling, inward, in trephination, 274, 278, 280, 281
Binocular loupe system, 297
Biopsy, 221–223, 243
Bitot's spots, 231
Bonn, University Eye Clinic, 299
Bowman's membrane
  destruction of, 334
  of donor eye, 276
  excision of, 205
  in Gundersen flap, 330
Bulbar conjunctiva in hood flap, 336
Bullous keratopathy
  and flap surgery, 330, 332, 333, 340–343
  EKP in, 384
  penetrating keratoplasty in, 363
  success rate in surgery, 373
Burke, technique of, 185
Burns, chemical, 229–230, 238, 255, 256, 289, 333–334, 363–365, 413
Buttonholes (tissue), 334, 335, 336, 338

Cancer and donor eyes, 314, 322, 323, 324
Cannulation, intraocular, 394–395
Carbon dioxide for freezing, 261
Carbonic anhydrase inhibitors, 273
Cataract, 198, 256, 352, 356, 417
Cataract extraction, 273, 274
  combined with graft, 207–209, 211, 363, 364, 376, 395, 396, 401, 414–415
  failure of, and keratoprosthesis, 211
  and microsurgery, 301, 411
  sutures in, 311
Cathode ray tube, 253
Cauterization vs. idoxuridine, 191
Cautery in closure of puncta, 239
Cazenave's disease, 228
Chair, "armrest," 300
Chandler's syndrome, 375
Chiseling of cornea, 261
Chloromycetin, 383, 384
Chymar, *See* Alpha-chymotrypsin
Collagenase
  in healing of lamellar grafts, 412, 413
  released in pemphigus, 229
Collagen disorders with Sjögren's syndrome, 223
Collagen, transparent, for soft lens, 269
Cone, location in graft, 420–421
Conjunctival flap. *See* Flap(s)
Conjunctivitis
  chronic, in pemphigus, 228
  purulent, and use of lenses, 383
  in Stevens-Johnson syndrome, 226
Contact lens(es)
  in dry eyes, 235–238
  hard, 413
  in keratoconus, 200–201, 211, 419
  methylmethacrylate, 263
  plastic, Czechoslovakian, 270
  removal at night, 382–383
  scleral, vs. corneal, 200, 201, 204, 237–238
  silicone, 263
  soft, 238, 245, 269, 379, 381, 391
  in corneal edema, 188
  vs. flush-fitting, 383–384
  vs. keratoplasty, 344
  and surgery, 198–199
Contact-lens lathe, 261
Cornea
  host, condition of, 315
  thickening with pressure, 398
Corneal rotocutter-Mark I, 303
Corneal tests, 192–193, 197–199
Corticosteroids in penetrating graft, 273–284
Cortisone in postoperative care, 212
Cryoextraction technique, 414
Cryopreservation. *See* Freezing
Cryoprobe, 366
Cyanoacrylate adhesive, 237
Cyclo-cryotherapy vs. cyclodiathermy, 393
Cysts after flap surgery, 339–340

Death of donor and use of tissue, 275
Debility and donor quality, 315
Decompression, rapid, dangers of, 280
Dehydrating agents in edema, 188
Dellens, 231–232
  and collagenase, 245
Dendritic figures, 190, 191
Depo-Medrol, 284
deQuengsy, artificial cornea, 181, 182
Descemetocele, 333, 360
Descemet's membrane, 274, 281
  in donor eye, 318
  in Fuchs' dystrophy, 403
  rupture of, followed by edema, 201–202
  in trephination, 274, 278
Desiccated eyes, staining in, 220
Desiccation keratitis, 233, 236, 239
Diamox, 213, 399, 400
Diathermy punctures, 286
Dimethylsulfoxide, sucrose and, 321
Diseases, systemic, of donor, 314, 324
Donor(s)
  age of, 315, 365, 374, 406
  early use of, 183

Donor eyes
arcus senilis in, 409
availability of, 264
from cadavers, 184
care of, 320–322, 374
contraindications for use, 322–323
cornea in lamellar graft, 290–291
cryopreserved vs. fresh, 407
endothelium, preservation of, 271
evaluation of, 317–320
fresh, storage time of, 315–316, 317
graft preparation, 275–279, 290, 291
lamellar dissection of, 268
selection of, 274–275, 313–315
utilization time, 273, 275, 315–316, 365
Donor tissues and stroma growth, 295
Dressing after surgery, 367
Drugs, parasympathomimetic, 235
Dry eyes and soft lenses, 384
Dry eye syndromes, 215, 219–233
biopsy in, 243
and corneal surgery, 203–204
EKP in, 384
treatments of, 233–240
Dry spots, 220–221
in chemical burns, 230
increase with aging, 241–242
postoperative, 233
Dye tests for tear volume, 219
Dystrophies and penetrating grafts, 202–203, 350, 352, 354, 362

Ectasia
contact lenses in, 201
diffuse. *See* Keratoconus
Edema, 355, 361
absence in Tenon's free flap, 343
epithelial, 417–418
in Fuchs' dystrophy, 417
and intraocular pressure, 391, 399
medical therapy of, 187–188
in penetrating graft, 355, 359, 361
and recipient dissection, 281
and reoperation, 292
Schiotz tonometry in, 387
and soft lenses, 379, 382
from vitreous contact, 284
EKP (of Kaufman), 384–385
Electrokeratotome (Castroviejo), 289
Endothelium
of donor eye, 188–189, 318
of graft, long-term fate of, 405–406
inadvertent injury to, 272
in penetrating keratoplasty, 282
technique of Fine, 274, 277, 278
and retrocorneal membrane, 294–295
traumatizing of, 366
Enucleation, 316, 324
Enzymes, 211, 212, 238–239, 413
Epikeratoprosthesis, 201, 380, 387
Epithelial covering, time required, 374
Epithelial regrowth and glued lens, 237
Epithelium
in avitaminosis A, 231
of donor eye, 276, 318
in Gundersen flap, 330
in postoperative care, 368
and postoperative pressure, 398
and retrocorneal membrane, 294
Erosions, 381, 382
Erythema exudativum multiforme, 225
Ethicon GS-9 and GS-10, 300
Evaporation and epithelium, 241, 245
Eye Bank Association of America, 322
Eye Bank for Sight Restoration, 263, 264, 269
Eyeglasses in postoperative care, 369
Eyelids, herpetic lesions around, 189
Eyes. *See* Donor eyes; Recipient eye

Fibroblast, 294, 295
Flap(s). *See also* Gundersen flap
apron, conversion to bridge, 336
erosions, postoperative, 339
peripheral "sliding," 332
postoperative course, 337–340
removal of, 340–342

Flap(s)—*Continued*
temperature of tissue in, 405
thick, 330, 333, 343–344
thin conjunctival, 329, 330–334, 335, 404
Flap retraction, 338–339
Flattening of cornea and pressure reading, 388–389, 392, 394
Flieringa ring, 284, 285, 288, 366
Florida, University of, 381, 393
Fluid, serous, in flap surgery, 331, 333
Fluorophotometry, 220
Fluorescein, 242, 290, 418
in applanation tonometry, 388
and epithelium, 241
in lamellar dissection, 268
leak test for sutures, 303
staining action of, 220
in trephination, 277
Forceps, 290, 299, 304, 306, 307, 367, 368
Foreign matter in lamellar graft, 291
Freezing, 263, 264, 321, 407, 408
Frequencies, ultrasonic, 253
Frigitronics unit, 393
Fuchs' dystrophy, 403
and combined procedure, 208, 209
diffuse, 209
and donor age, 315
indications for surgery, 362, 417, 419
and iris surgery, 366
medical therapy in, 187–188
and regraft, 292
Fungus infections of cornea, 192–196

Gill knife, 289, 290
Glaucoma, 361, 387
in aphakic keratoplasty, 284
and conjunctival flap, 340
and penetrating graft, 350, 357–361
postoperative, 390, 392–394, 414
and quality of donor eyes, 313–314
secondary, vitreous contact, 284
and soft lenses, 380, 384
Globe, disorganized, ultrasonogram, 258–259
Glucose and epithelium, 241
Glycerin, 321, 393
Glycogen in epithelium, 240
Goblet cells, 222
in avitaminosis A, 231
disappearance of, 240–241
in lining of hood flaps, 343
and mucus membrane graft, 243
mucus produced by, 217
in Sjögren's syndrome, 224
and Stevens-Johnson syndrome, 227
Goggles in tear deficiencies, 235
Graft cut, 186, 272
Graft failure
caused by technical errors, 271
correction of, 291–292
repeated, keratoprosthesis in, 201
retrocorneal membrane in, 293–295
Graft reaction. *See* Homograft reaction
Griffin lens, 382
Gundersen flap, 329–331, 333, 334, 336

Hashimoto's thyroiditis, 224
Hemangioma, of choroid, 259–260
Hematoma, ultrasonic diagnosis, 259
Hemorrhage
after flap surgery, 338
from iridectomy, 281
retrobulbar, 274
vitreous, and ultrasonography, 259
Hepatitis, infectious, in donor, 314
Herpes virus, 190–192, 194, 195
Heteroplasty, animal experiments, 182
Homograft reaction, 188–189, 292, 293, 323, 371, 372, 374–375, 376–377, 406, 409
Hydronol, 393
Hydrophilic lens in dry eye, 203–204
Hydrops, 201–202, 211
Hydroxypropylcellulose, 244
Hydroxypropylmethylcellulose, 244
Hygroscopic solutions in edema, 187
Hypercholesterolemia, 410

Hyperosmotic agents, oral, 392–393
Hypovitaminosis A, 230

Idoxuridine (IDU), 191, 244, 403–404
IK. *See* Keratitis, interstitial
Infection. *See also* Bacterial infection
  and quality of donor, 314
  after use of soft lenses, 383
Inflammation
  postoperative, minimizing, 372–373
  and quality of donor, 314
International Eye Bank, 317
Intraocular pressure
  importance of accuracy, 392
  measurement and control, 387, 388
  in surgery, 211–212, 213, 219
Iridectomy, 198, 311, 356, 366
  peripheral, in recipient trephination, 280, 281
  subtotal, 354
Iridotomy, 350, 354, 356, 366
Iris adhesions, 370, 422
Iris atrophy, essential, 375
Iris repair, 310–311
Iris surgery
  omission of, 373
  and penetrating grafts, 348–366
Iris suturing, microscopic, 302
Iritis, herpetic, 404
Irradiation, excessive, 295
Isosorbide. *See* Hydronol

Jaundiced eyes as donor material, 325

Kasner removal of formed vitreous, 366
Keratectomy, 202, 204–205, 206–207
  superficial, in Gundersen flap, 330
Keratitis
  chronic herpetic, 332, 339, 341, 352
  drug-resistant, thin flap in, 329
  exposure, 233, 236, 239
  fungal, 404
  herpetic, 189–193, 343, 411
  interstitial, 199, 314, 352, 356, 410
  mycotic, 405
  neuroparalytic, 234, 384
  neurotrophic, 233
  and penetrating graft, 363–364
  and peripheral iridectomy, 281
  punctate, and steroid therapy, 370
Keratitis sicca, 244–245, 380
Keratoconjunctivitis, 230, 242
  vs. herpes simplex keratitis, 190
Keratoconjunctivitis sicca. *See* Sjögren's syndrome
Keratoconus, 200, 302
  acute, 201–202
  bulging, on suture removal, 370
  and donor age, 315
  indications for surgery, 417–419
  intraocular pressure in, 401
  keratoplasty in, 199–202
  penetrating graft in, 348, 350
  and recipient dissection, 281
  and regraft, 292
  success rate in surgery, 362
  sutures left in place, 309
  and wearing of soft lenses, 383
Keratoglobus, 419
Keratoiritis and iridectomy, 281
Keratomalacia, 231
Keratome, 263, 289
Keratometer, 198, 200, 201, 301–303, 418
Keratomileusis, defined, 261
Keratophakia, defined, 261
Keratophakotome, 263
Keratoplasty
  cataract with central corneal scars, 198
  and combined lens extraction, intraocular pressure in, 390
  diagnostic ultrasonography in, 259
  in dry eye syndromes, 238–239
  early work in, 184
  indications for, 199–204
  lamellar. *See* Lamellar grafts
  refractive, defined, 261
  after thin flap, 341–342
Keratoplasty patient and microsurgery, 301
Keratoprosthesis, 209–211
Kerototorus, contact lens in, 201

Knot burying, 304–308, 351, 353, 371, 424
Knot, surgeon's, 367

Laceration, corneal, 258
Lacrimal glands, 217
  infected, and herpes virus, 190, 194
Lamellar grafts, 184–185
  on animals, 183, 264
  applications for, 263–268
  with autokeratome, 264–268
  and Cardona keratoprosthesis, 210
  fungal ulcer after, 193–194
  incision in, 290
  lipids in, 411
  vs. penetrating grafts, 201, 202, 264, 272–273, 289–291
  preservation of donor eyes, 320–321
  in pterygium, 206, 207
Lens. *See also* Contact lens(es)
  in keratophakia, 261
  as sonic focus device, 255, 256
Leptospira, 325
Leukemia and donor material, 314, 322, 324
Leukoma, 198, 206, 257
Lipid layer of tear film, 216
Lipoidal degeneration and healing of transplants, 408, 410
Loupes, standard, in flap surgery, 334
Lyophilization, 321

Manhattan Eye, Ear and Throat Hospital, use of soft scleral lens, 269
Marcus rules for transplant, 182
Marginal strip, inspection of, 219
Maryland, Medical Eye Bank of, 364–365
Medical-legal aspects, donor eyes, 323
Medical therapy, use with soft lens, 379, 383, 384
Medications after flap surgery, 337
Meibomian gland secretions, 216
Membrane, retrocorneal, and failure in corneal grafts, 189
Methylcellulose, 234, 255, 380
Methylmethacrylate in soft lens, 269
Methylprednisolone, injection of, 288
Microkeratome, 263
Microscope, 416
  for donor material, 318
  fixed power, 297–298
  in flap surgery, 334
  operating, 297, 298, 347, 365
Microsurgery, 299, 300, 301, 310, 347, 373
Miochol, 283, 287
Mortician, and donor eyes, 316, 323–324
Mouth, relation to dry eye, 244
Mucoid layer of tear film, 217–219
Mucous membranes, 226, 228
Mucus
  conjunctival, and corneal epithelium, 218
  in dellen, 232
  role of, 231
  and stability of precorneal tear film, 240
Mucus deficiency, 220, 221, 227, 235
Mucuslike tear substitutes, 244–245
Mucus in Sjögren's syndrome, 224
Myopia, penetrating graft in, 350

NaCl ointment, 333
NBT stain, 319–320
Needles, 277, 282, 299, 300
Neomycin, 384
Neosporin and donor eyes, 274, 316
Nitrogen, liquid, 321–322, 408
Nutrition and goblet cells, 240–241
Nystagmus and penetrating graft, 202
Nystatin, 196, 404

Ointment, steroid-containing, 367, 369
Opacification and penetrating keratoplasty, 364, 365
Opaque grafts, reoperation of, 209
Open-sky technique, 211, 366, 376, 414, 415
Ophthalmia, sympathetic, 311
Optics, field-focused, 299

Pachymeter, 200, 399
Palpation vs. instruments, 397–398
Pannus, subepithelial, in Stevens-Johnson syndrome, 226, 227
Paraffin, liquid, 321
Paralysis, seventh nerve, 234
Parotid duct transplant, 239–240
Patching and inflammation, 373
Peeling process in flap removal, 341
Pellucida, contact lenses in, 201
Pemphigus, 226–229, 244, 382
Penetrating graft(s), 271, 341
  data in 40 cases, 348–361
  and donor quality, 313
  after Gundersen flap, 330, 333
  indications for, 362–364
  partial, 272–273
  postoperative management, 367
  and preexisting cataract, 364
  preoperative treatment, 273
  preservation of donor eyes, 321–322
  surgical techniques, 274–289, 364–367
Perforating injury, surgery in, 363
Perforation
  avoidance of, in trephination, 276
  in lamellar grafts, 289–290
Phospholine Iodide, 212
Photography followup in scarring, 200
Photophobia, 241
Phthisis bulbi
  and conjunctival flap, 340
  and donor quality, 314
  ultrasonogram, 258–259
Pilocarpine, 235, 273, 368, 383, 384
Pimaricin, 196, 404
Pneumonia, nonbacterial, in Stevens-Johnson syndrome, 226
Polyvinylpyrrolidine, 321
Postmenopausal Sjögren's syndrome, 223
Preservation of grafts, 184
Prognosis, 199, 413
Prostheses
  in dry eye syndromes, 239
  plastic, dellen effect, 245
Prosthetic shell, 337
Pseudopterygiums, 205–207
Pterygiums, 205–207
Ptosis, protective, and flap, 340
Puncta, closure of, in keratoconjunctivitis sicca, 239
Punctate staining, 242
Pupil, dilatation of, 369
Pupillary block, iridectomy in, 280, 281
PVP. *See* Polyvinylpyrrolidine

Reaction, late immune, 406–407
Recipient eye, 265, 266–268, 271, 279–284
Refraction with ultrasound, 260
Regraft. *See* Graft failure
Retina, detached, and ultrasound, 256, 257
Retrocorneal membrane, 293–294
Retrograft membranes, 279
Rose bengal staining, 220

Saline
  hypertonic, 380, 383,
  normal, as tear substitute, 233
Saline solution in suturing, 367
Salivary glands and herpes virus, 194
Salt, balanced, sterile solution, 282, 283
Salvage, and "early" grafting, 364
Scanning in ultrasound, 260
Scars
  central and paracentral, keratoplasty in, 199
  keratectomy in, 205
  semitransparent, 198
  in Stevens-Johnson syndrome, 238–239
Schirmer test, 219, 229, 233, 239
Scissors, 277, 278, 279, 305
  in recipient dissection, 286, 287
Sector wedge resection, 302, 309
Sex, and graft results, 348, 352–360
Sialoadenitis, Sjögren's syndrome as, 224

Sjögren's syndrome, 220, 223–225, 238
Slit lamp, 200, 219, 260
  and dry spots, 242
  and microscope, 298, 300
  preoperative examination, 280
  and suture removal, 309
Sodium chloride ointment, 187, 188
Soflens, 204
Spectacles
  for keratoconus, 200
  postoperative, 349–370
Staining methods, donor eyes, 319–320
Stevens-Johnson syndrome, 225–228
  case histories, 203–204
  conjunctiva from, 222
  keratoplasty, 238
  soft lenses in, 380
Steroid therapy, 211, 212, 369
  contraindicated in dendritic figures, 191
  intensive, in nonulcerative herpes, 192
  in keratitis sicca, 244
  for ocular inflammation, 372
  and thinning of cornea, 193
Storage, eye bank, 316–317
Stroma
  of donor eye, 318
  and retrocorneal membrane, 294, 295
Stromal thickening and soft lens, 379–380
Suction pump in lamellar grafts, 265
Suction rings, placement of, in lamellar graft, 264–265, 268
Sulfa in keratitis sicca, 244
Suspended-loupe system, CM-11, 298
Suture(s)
  continuous, 307, 330, 347–362, 367, 370, 371
    vs. interrupted, 421–422
  double-continuous, 303, 423–424
  Ethilon (10-0), 283
  interrupted, 303, 336
  in lamellar graft, 291
  left in place, 296, 309
  Lucite container for, 278, 279, 281
  for microsurgery, 299–300, 303–310, 411
  monofilament, 304, 307, 310, 347–362, 367, 371, 423
  nylon (10-0), 282
  overlying, 184, 185, 186
  for penetrating keratoplasty, 277, 278
  preplaced, 284, 285, 288
  for recipient cornea, 281–283
  symmetrical continuous, 268, 269
  virgin-silk, 365, 366
Suture removal, 308–309, 371, 424
  in penetrating grafts, 349–361, 369
  premature, 294, 370
  in thin flaps, 337
Suture tension, 283
Sweat glands and herpes virus, 194
Symblepharon, 223, 227, 237
  fitting of soft lenses, 381–382
  in pemphigus, 228, 229
Symptoms, relief of, vs. surgery, 344
Syphilis and donor material, 314, 325

Tarsorrhaphy, in exposure keratitis, 239
Tear deficiency in Sjögren's syndrome, 224–225
Tear film
  in avitaminosis A, 231
  breakup point, 220, 233, 234, 240, 241
  in chronic keratoconjunctivitis, 230
  continuous precorneal, 218-219
  in pemphigus, 229
  physiology of, 215–219
  in Stevens-Johnson syndrome, 227
  tonicity of, 242
Tear substitutes, 233
Tenon's capsule, 329, 330, 334, 335, 336
Tetracycline, 273
Thermaphore, and fungal ulcers, 194
Thickness gauge in lamellar dissection, 267

5 thorocytin, 404
Throw, triple, 304
Tonometry, 387–395, 400
Topogometer. *See* Keratometer
Trabeculotomy, 302
Trachoma, 230
Transducer in ultrasonography, 254, 255, 257
Transillumination, 197
Transparency in lamellar grafts, 289
Trauma, 356, 357
Trephination, 273, 365
Trephine
  for donor eye, 274, 275–279
  in flap removal, 341
  in lamellar grafting, 290
  manual vs. motor-driven, 275
  for recipient cornea, 279
  semiautomatic, 303
  von Hippel's, 183, 184
Trichiasis in pemphigus, 229
Trypan blue stains, 319, 320
Tubingen, University Eye Clinic, 299
Tumors, 314, 324

Ulcer(s)
  central corneal, 404
  corneal, and flap surgery, 332, 338
    tarsorrhaphy in, 239
  fungal, 193, 332, 342, 349
  lens protection of epithelium, 381
  Mooren's, 334
  pseudodendritic, vs. herpes keratitis, 190
Ultrasound (ultrasonography), 253–255, 257–258
  in testing for surgery, 197

Vacuum ring, lamellar dissection, 268
Variac transformer control, 298
Vascular congestion in dissection, 280
Vascularization, 365, 369, 372, 409
Vision, preoperative and postoperative, 348–360
Visual acuity, postoperative, in correction for hyperopia, 270
Visual loss and pressure, 399
Vitrectomies, 302, 363, 373, 376, 396
Vitreous, fluid, aspiration to soften globe, 285, 286
  prolapse of, in trephination, 284
Vitreous contact, danger in aphakia, 284

Wessely ring, 190
Wheeler knife, 277, 280, 286, 287
Wilmer Institute technique, 331, 334–336
Wound
  appearance of, determining regraft, 293
  healing as function of graft diameter, 295–296
  testing of, 283, 367
Wound closure
  and continuous suture, 303, 422–423
  firm, 279

Xerophthalmia, 215, 233
Xerosis in dry eye, 239

Zirm grafting technique, 183–184

Index

Abscess, and bacterial protoplast, 495
Absorption spectrum, 601
Achromotrichia, 556
Acthar gel, 643
ACTH, intravenous, 643
Action spectrum, 601
Acyl esterase, 506
After-image, persistence of, and clomiphene citrate, 618, 619
Age and retinopathy, 629, 630
Allergic reactions, 466
Ametropia, 630
Amidase, 496, 507
Aminoquinolines, 575
Ampicillin, 500–501, 502
Angiography, fluorescein, 580
Antibacterial agents, 473
  route of administration, 479–482
Antibacterial spectrum, and cephalosporins, 508
Antibiosis, principle of, 474
Antibiotics
  bacteriostatic, and cephalosporins, 505
  true, 474, 516
    benzylpenicillin as, 493
    and sulfonamides, 484, 485, 491–492
Antibiotic transport, problem of, 480
Antibody levels and toxoplasmosis, 624–625, 628
  in ocular toxoplasmosis, 622
Antidepressants, 663
Antimetabolite therapy, 645
Antimicrobial agents, 482–536
  inhibitory concentrations, 480
  sensitivity of bacteria to, 487
  sulfonamides as, 485
Antimicrobial therapy, 473–482, 641
Arteritis and headache, 659–660
Arthritis, rheumatoid, and chloroquine substitute, 580
Atrophy, optic, and chloramphenicol, 614

Bacitracin, 535–536
Bacterial penicillinase and methicillin, 503–505
Bactericidal agents, 475
Barriers, physiological, 480
  and chloramphenicol, 516
Benemid. *See* Probenecid
Benzydamine and scintillating scotomas, 609
Benzylpenicillin, 493, 497, 499–500
Blepharoconjunctivitis, allergic, 533
Blood levels
  and ampicillin dosage, 501
  and cephaloridine, 510
  and fucidin, 532
  after intravenous injection, 499
  after oral antimicrobial administration, 481
  with repository penicillins, 497
Body weight and chloroquine retinopathy, 560
Brain tumor and traction headache, 659
"Bull's eye" lesion, 565

California District Court of Appeals, on package insert, 462–463
Care, standard of, 461, 462
Cataract(s). *See also* Opacities
  anterior polar capsular, 593
  and antimalarial therapy, 558
Catecholamines and blood vessels, 653

Cats
  chloroquine retinopathy, 568–569
  toxoplasmosis and, 644
Cephalexin, 511
Cephaloglycin, 511
Cephaloridine, 510–511
Cephalosporinase, 507
Cephalosporin C, 508
Cephalosporins, 505–511
  and penicillin resistant organisms, 507
Cephalosporium acremonium, 505
Cephalothin, 508–510
Cervical osteoarthritis, 657
Charge transfer complex, 575, 599
Chemotherapeutic compounds, 474
Chloramphenicol, 475, 515–518, 614–616
  and blood dyscrasias, 467
Chloroquine, 555–580
  cellular binding of, 570
  and eye complications, 458
  and long-term oral administration, 574
  melanin-bound, retention in eye, 574
  methods of increasing excretion, 576
  ocular deposition of, 570
  prolonged retention in body, 572–573
  properties of, 570–576
Chlorpromazine, 587–602
  biochemical mechanisms, 597–601
  cardiovascular symptoms, 589
  clinical descriptions, 590–595
  dermatological reactions, 589
  experimental pathology, 595
  extrapyramidal reactions, 589
  hematological symptoms, 588
  human pathology, 596
  solution, oxidation of, 598
  systemic side effects, 588–589
Chlortetracycline, 475
Choroidal fluorescence, 579
Choroiditis, juxtapapillary, of Jensen, 631
Ciliary body and chloroquine, 558
Clinical investigation, medicolegal aspects, 468–470
Clomiphene citrate, 617–619
Cloxacillin, 501, 502
Cluster headache, 655, 663
Colistin, 524–525
Color vision
  in chloroquine retinopathy, 568
  tests, 578
Compensation in drug injury, 455–456
Congeners of sulfonamide, 488, 489
Conjunctiva, pigmentation, 590, 591
Conjunctivitis from *Toxoplasma*, 637
Consent, informed, 465, 469–470
Contraceptives, oral, and ocular abnormalities, 604–607
Conversion reactions, 658
Copper, body storehouse of, 600
Cornea
  and chloroquine, 557–558
  and chlorpromazine, 590, 592
    granularity from, 595
Corticosteroid therapy, 642–644
  in chorioretinitis, 640
Cramps of feet and toes, and chloramphenicol, 614
Cross resistance, bacterial, 534
Cryotherapy, 644–645
Cyclic administration of antimicrobial agents, 482
Cyclophosphamide, 645
Cyproheptadine, 662
Cysts
  in chorioretinitis lesion, 627
  in toxoplasmosis, 626, 628, 631
    rupture of, 639

Daraprim. *See* Pyrimethamine
Dark adaptation
  in retinopathy, 568
  tests, 578
Demethylchlortetracycline, 514
Depression and headache, 658, 663

Detail men and adequate warning, 458
Dichloronitroaniline, 601
Dicloxacillin, 501, 502
Dimethyl sulfoxide (DMSO), 609–613
Doctor–patient relationship, 460
Dopa reaction, 596
"Doughnut" lesion, 565
Doxycycline, 514
Drug allergy, cephalosporins, 507–508
Drug intake, history of, 466
Drugs
  antibacterial, 474
  experimental, 468–469
  in headache therapy, 663
  investigational, regulations on, 470–472
  misuse of, 467–468
  systemically administered, ocular side effects, 553, 554
Drug toxicities, 553

Edema
  brain, produced by migraine, 656
  papillary, 636
  in photosensitivity, 601
Electromyography and muscle contraction, 657
Electrooculogram, 568, 577
Electroretinogram, 568, 577
Enzymatic destruction, 476–478, 506
Enzymes, 496, 507
  intracellular, inhibited by chloroquine, 576
  protective, 477
Ergot alkaloids, 653
Ergot therapy, 662–663
Erythromycin, 520–522
  structure of, 521
Excretion
  biliary, of fucidin, 532
    of novobiocin, 525
  renal, and cephaloridine, 510
    and cephalothin, 508
    and chloramphenicol, 516
    and classification of sulfonamides, 490
    of kanamycin, 534
    and penicillin G, 499
    of tetracyclines, 513
Eye
  in drug toxicities, 553, 554
  malformations from toxoplasmosis, 629–630

Farnsworth D-15 panel color objects, 568
Federal Food, Drug and Cosmetic Act, 456, 470
  1962 amendments, 459
Fluorescein photography, 579
Folic acid. *See* Pteroylglutamic acid
Folinic acid in thrombocytopenia, 642
Food and Drug Administration (FDA), 457, 553
Foyer en rosace, 633
Fucidin, 532
"Full disclosure," 457
Fundus
  in chloroquine retinopathy, 564–566
  and chlorpromazine, 594
  toxoplasmosis in, 624, 630

Gentamycin, 530–531
Glaucoma, progressive lesions in, 631
Glossopharyngeal neuralgia, 661
Glycine bridge closure, 493
Gram-negative organisms
  and gentamycin, 531
  and lincomycin, 528
  and production of amidase, 496
Gram-positive cocci and novobiocin, 525
Gram-positive organisms and fucidin, 532
Gram stained smears, 479

Hair, bleaching of, 556

Headache drugs, side reactions, 648
Headache(s), 647
  classification of, 649
  hangover, 657
  toxic vascular, 656–657
  treatment of, 662–664
Helsinki Code of Medical Ethics, 469
Hematomas as cause of headache, 659
Hepatitis, drug-induced vs. toxic, 588
Hepatotoxicity and chlorpromazine, 588
Histamine and microcirculation, 652
Histamine-glucocorticoids relationship and migraine, 652
Histamine sensitivity and migraine, 655
H-R-R pseudoisochromatic color plates, 578
Hyalitis, 631
Hydrocephalic infant, 621
Hydroxychloroquine, 555, 558
Hypersensitivity and toxoplasmic retinochoroiditis, 639
Hypoglycemia and headache, 657

Iatrogenic disease, 553
IND. *See* Investigational new drug application
Indomethacin, 608–609
Infection(s)
  acute ophthalmic, 478
  chronic, 478
  deep orbital, 479
  intraocular, 479, 480
    and bactericidal agents, 515
    and sulfonamides, 492
    tetracycline therapy, 514–515
  intraorbital, 480
  intrauterine, 629
    toxoplasmic, 626
  laboratory acquired, 623
  prenatal, 628–629
    and toxoplasmosis, 637
  toxoplasmic, 622
    and pyrimethamine, 640
  tuberculous and streptomycin, 520
Injection
  of cephalothin, 508
  intramuscular, contraindicated, 482
    of gentamycin, 531
  intravenous, of antimicrobial agents, 482, 483
    intermittent, 499
    and penicillins, 497
    and methicillin, 504
    and tetracyclines, 514
    of vancomycin, 527
  of polymyxin, 524
  of streptomycin, 518
Intraocular penetration of antimicrobial agents, 484
Investigational new drug application, 471
Iridocyclitis
  primary toxoplasmic, 636
  secondary, 630

Judgment, medical, 461–463

Kanamycin, 534–535
Keratopathy
  acute phototoxic, and phenothiazines, 595
  chloroquine; 557–558
  corneal, in animals, 601
  epithelial, 593

Lavage, corneal, for external infections, 525
Lens
  changes with chlorpromazine, 590
  and chloroquine, 558–559
  effect of dimethyl sulfoxide, 612
Lenticonus, posterior, 630
Lesion(s)
  jellyfish, 634, 635, 636
  juxtapapillary, 631
  mass, as cause of headache, 658–659
  rosette-type, 633
  self-limiting hyperergic, 631

Leukopenia and chloroquine, 557
Leucovorin, 642
Light photostress test, 578–579
Lincomycin, 528–529
Liver reactions and chloroquine, 557
Lysergic acid derivatives and headache, 652

Macula
  in chloroquine retinopathy, 564
  pigmentary degeneration and chlorpromazine, 591
Macular dazzle test, 578–579
Manufacturer (drug)
  recommendations of, 462
    deviation from, 463
  responsibility in injury, 456–460
Masson-Fontana silver method, 597
Mast cells and migraine, 652
Melanin capture of free radicals, 599
Melanin-chlorpromazine moiety, 597
Melanin granules
  absorption of chloroquine, 571
  interference with function of, 575–576
Melanin pigment
  effect of chloroquine, 556
  preferential binding of drugs to, 571
Melanin synthesis and tyrosinase, 600
Melanosis, 590
Mellaril. *See* Thioridazine
Membranes, penetration of, and dimethyl sulfoxide, 610
Methicillin, 503–505
Methoxsalen, 601
Methysergide, 652–653, 662
MIC, 480
Microphthalmia, 630
Migraine, 647
  classic, 650–654
  common, 654–655
  concepts of, 654
  hemiplegic, 655–656
  ophthalmoplegic, 656
  and oral contraceptives, 605
Migraine equivalents, 651
Monamine oxidase inhibitors as cause of headache, 657
Motor syndromes, convulsive, and chlorpromazine, 589
Muscle contraction headache, 657–658
Myositis, chronic, 657

Nafcillin, 503
Nasal disease and headache, 660
Neck structures, disease of, 660–661
Negligence in drug injury, 455–456, 461
Neomycin, 532–533
Nephrotoxicity, 533
Nerve deafness and chloroquine, 556
Neuralgias, 661–662
Neuritis
  cranial, 661–662
  optic, 614
  peripheral, 614
Neurokinin, 651
Neuromyopathy and chloroquine, 557
Neuroretinopathy, toxoplasmic, 626, 630–636
Nitrofuran derivatives, 492
Norepinephrine, 654
Norethynodrel with mestranol, 606
Novobiocin, 525–526
NP-207, 600

Ocular abnormalities and oral contraceptives, 604–607
Ocular diseases, iatrogenic, 608–609
Oleandomycins, 522–523
Opacities
  and chlorpromazine, 591–595, 600–601
    vs. axial punctate, 594
  lens, and norethynodrel with mestranol, 606
    related to dimethyl sulfoxide, 611
  in phenothiazine therapy, 589
  punctate lens, and oral contraceptives, 605

Optic nerve
demyelinization of, 615
in toxoplasmosis, 636
Ophthalmologist, role in headache diagnosis, 649
Oral administration, 481
of gentamycin, 531
and sulfonamides, 488
Organogenesis and prenatal infection, 629
Ototoxicity, 533
Oxacillin, 501, 502
Oxytetracycline, 514

PABA. *See* Para-aminobenzoic acid
Palsy, ocular, 656
Papillitis. *See* Neuritis, optic
Para-aminobenzoic acid, 486
Paramycin, 535
d-Penicillamine as copper chelating agent, 600
Penicillinase, bacterial, and ampicillin, 500
Penicillin G. *See* Benzylpenicillin
Penicillin(s), 493–505
adverse reactions, 499–500
basic nucleus, manipulation of, 493
and cephalosporins, structural relationship, 496
isoxazolyl, 501–503
penicillinase resistant, 495
potassium, 499
procaine, 497
properties and dosage of, 498
semisynthetic, 493, 495, 496, 501–503
sodium, 499
Penicillin V, 500
Penimepicycline, 642
Phenethicillin, 500
Phenothiazines, 571, 575, 590, 595, 662
affinity for melanin, 599
Phenoxy penicillins, 500
Phospholine Iodide, 465
Photoactivation, 598
Photosensitivity and chlorpromazine, 601
Physician
duty to warn, 464–466, 553
and experimental studies, 469
responsibility of, 456, 460–463
Pigmentary disturbances and chloroquine retinopathy, 562–563, 564
Pigmentation
and chlorpromazine, 589
chlorpromazine-melanin binding, 599, 600
generalized visceral, 594–595
retinal, after chlorpromazine, 594
Pigment granule, chlorpromazine, 598
Plasma protein binding and sulfonamides, 488
Poisoning, chloroquine, 556
Poisons, protoplasmic, 475
Polymixin B, 523
Polymixin E, 524–525
Polymixin in ophthalmology, 524
Polypeptides, 523
in migraine, 651
Postnatal disease, toxoplasmic infection in, 625–626
Prednisone, 643
Pregnancy and drug injury, 464
Prenatal disease, toxoplasmic infection in, 625–626
Probenecid, 499, 508
Pseudocoloboma, macular, 621, 633, 634
Pseudoglioma and toxoplasmosis, 634
Pseudomonas aeruginosa
and gentamycin, 530, 531
and penicillin G, 476
Pseudoneurotropy, 626
Pseudotumor of orbit, 660
Psychosis and chloroquine, 556
Pteroylglutamic acid, 486
Purple skin pigmentation, 600
Pyridoxine, 615

Pyrimethamine, 625, 639, 640–642
and sulfadiazine, 640, 641–642

Rabbits, chloroquine retinopathy, 569
Radical, free, 597
Rats and chloroquine retinopathy, 569
Reading difficulties and retinopathy, 566
Res ipsa loquitur doctrine, 460
Resistance
bacterial, to antimicrobial agents, 476–478
to cephalosporins, 505–507
common mechanisms of, 477
to gentamycin, 530
to penicillins, 495
to polymyxin, 523
to streptomycin, 518
to sulfonamide, 488
to tetracyclines, 513
to vancomycin, 527
intrinsic, 476
Resistant organisms, secretions of, 533
Retina, periphlebitis of, 634
Retinal degeneration
central, 565
peripheral, 565
Retinal detachment and serous exudate, 631
Retinal function studies, 577
Retinal lesions and indomethacin therapy, 608, 609
Retinochoroiditis, 639
Retinopathy
advanced stage, visual field in, 567
chloroquine, 559
and dosage, 559, 560, 561
incidence of, 562–563
human pathology, 570
presenting symptoms of, 564
chloroquine-melanin interaction in, 575
and congenital toxoplasmosis, 621
delayed, 627–629
direct, 627–629
duration of therapy, 561–562
early stage, 566
experimental pathology, 558–570
intrauterine, 630
juxtapapillary toxoplasmic, 632
moderate and advanced stages, 566
visual field in, 567
necrotizing toxoplasmic near scar tissue, 631
from prenatal infections, 628–629
relapsing, 627–629
toxoplasmosis as, 638
vascular, with cystic fibrosis, 615
visual prognosis in, 568
Ristocetin, 527–528

Sansert. *See* Methysergide
Satellite lesions, 629, 630
Saytzeff, Alexander, 610
Scar, resorbing toxoplasmic retinopathy,. 632
Scotoma(s), 566, 631
headache in, 651
paracentral, 618
pericentral, 578
scintillating, 609
Senile nuclear sclerosis, 611, 612
Sensitivity studies, 478, 479
Serotonin, inhibition by methysergide, 654
Serum antibody level in ocular toxoplasmosis, 624
Serum glutamic oxaloacetic transaminase (SGOT), 501
and isoxazolyl penicillins, 501
SGOT, 501
Side effects. *See also Adverse Reactions sections in discussions of specific drugs*
and duty to warn, 465
ocular, and chloroquine, 557–559
Skin
effects of chlorpromazine, 589, 590
reactions with chloroquine, 557

Skin testing, 466
Sodium sulfacetamide, 491
Spiramycin, 642
Staphylococci, tetracycline resistant, 513
Staphylococcus aureus, 508
  and fucidin, 532
  and gentamycin, 530
  and methicillin, 504
  penicillin resistant, 478
  production of penicillinase, 477
Strabismus in infant, 629
Streptococcus viridans and gentamycin, 531
Streptomyces venequelae, 515
Streptomycin, 518–520
  chemical structure of, 519
Subconjunctival injection, 499
  of cephaloridine, 511
  of gentamycin, 530
  and kanamycin, 535
  of neomycin, 533
Sub-Tenon's steroid injection, 643–644
Sulfisoxazole, 491
Sulfonamides, 484–493
  antibacterial spectrum, 486, 487
  and pyrimethamine, 640
  structure and chemistry of, 486
Sunburn reaction and chlorpromazine, 601

Temporal arteritis polymyalgia rheumatica complex, 660
Teratogenic effects of drugs, 464
Testing of drugs, adequacy of, 459–460
Test(s)
  for persistence of after-image, 618
  positive complement fixation, 623, 624
  positive dye, 624
  retinal screening in chloroquine therapy, 577–579
  for *T. gondii* antibodies, 623
Tetracyclines, 475, 512–515
  chemical structure of, 512
  properties and dosage, 515
Therapy, recommended, deviation from, 468
Thiabendazole, 644
Thioridazine, 589, 590, 594, 600
Tic douloureux, 661, 663
Topical therapy
  and bacitracin, 535–536
  and chloramphenicol, 517, 518
  and colistin, 525
  and erythromycin, 522
  and gentamycin, 530–531
  and kanamycin, 534
  and neomycin, 533
  and nitrofurazone, 492
  and novobiocin, 526
  and oleandomycins, 522
  and polymyxin, 524
  and streptomycin, 520
  and sulfonamides, 491
  and vancomycin, 527
Toxicities, ocular, of chloroquine, 555
Toxocara catii, 644
Toxoplasma gondii, 621, 626
  phenocopies, 629–630
  and pyrimethamine, 641
Toxoplasma organisms, formation of cysts, 627
Toxoplasmosis
  acute, 623
  as cause of uveitis, 639
  congenital, 621
  diagnosis, 622–625
  ocular, histopathology, 626–627
  pathogenesis, 625–627
  rare manifestations of, 636–637
  retinal, acquired, 636
  use of term, 621–622
Traction and inflammatory headaches, 658–662
Transpeptidase, 478, 493
  modified bacterial, 507
Trigeminal neuralgia. *See* Tic douloureux

Triparanol as cataractogenic agent, 617
Triquin, 558
Tyramine, 663

Units, conversion to milligrams, 493
Urinary output and sulfonamides, 490
Uterine bleeding and clomiphene citrate, 617
Uveitis
  antibody quotient, 625
  corticosteroids in, 642
  and toxoplasmosis, 624, 626, 639

Vancomycin, 526–527
Vascular headache, 649, 650–657
Vasodilatation in vascular headache, 656
Vasomotor functions, central, 653
Venous dilation and mestranol, 606
Vision, blurring of, and clomiphene citrate, 617
Visual field
  in early stage retinopathy, 566–567
  loss in chloroquine retinopathy, 567
Visual impairment and chlorpromazine, 594
Vitamin B complex and chloramphenicol, 616
Vitamin metabolism, interference of chloramphenicol, 616

Walsh, Frank, 604
Warning (of drug injury)
  adequacy of, 457–458
  recent and little-known, 463–464
Window glass and phototoxic drug reactions, 601
Withdrawal as cause of headache, 657
Work-up in chronic headache, 648–650, 662

Yarrow vs. Sterling Drug, 458

Index

Adaptic, in burn treatment, 860
Albinism, cosmetic lens for, 771, 773
Alcon, 832
Alginate, in impression fitting, 739, 740, 742, 748–749, 778
Amblyopia, prosthesis for, 773, 804
Anatomy of eye, restoration of, 843
Anophthalmia, congenital, 879, 880–883
  conformer for, 882, 883–884, 903
  and cul-de-sacs, 882
  implants for, 881
  mucous membrane graft for, 883
  prosthesis for, 773
  and prosthetic fitting, 817
  and ptosis, 817
  skin graft for, 883
Anophthalmos. *See* Anophthalmia, congenital
Antibiotics
  for chronic irritation, 833
  following skin graft, 827
  for lid burns, 859, 861–862
  for preoperative infections, 730
  prophylactic use, 730, 732
Atrophied globe
  prostheses for, 718, 764, 777–778
    scleral cosmetic, 767, 768, 779

Bacterial incubation, potential, 717, 737–738, 802, 838
Bell's phenomenon, 803
Bell's palsy, 860
Blepharitis, and conformer, 905
Blepharoptosis. *See* Ptosis
Bone graft, 793–796, 892, 893
Burns. *See* Chemical burns; Thermal burns

Canthotomy, 906
Canthus, inner, and scleral lens, 768
Cartilage graft
  and exenterated socket, 892
  for sulcus deformity, 793
Casting. *See* Stone casting, in fabrication of prosthesis
Casting shell, 800. *See also* Prosthetic fitting
Castite, 805, 806, 807
Cataract, prosthesis for, 765, 773
Chemical burns
  caustic, and loss of cul-de-sac, 827, 829
  classification of, 860–861
  emergency treatment of, 861
  irrigation for, 861
  of lids, 859, 860–863
    treatment of, 861–863
  scleral cosmetic prostheses for, 873
Chiasm, in enucleation, 724
Chloromycetin, 827
Choroidal material, in evisceration, 730, 732
Coloboma, cosmetic prostheses for, 765, 768, 770, 773
Conformer
  acrylic, 882, 883
  complications of use, 905–906
  in congenital anophthalmia, 882, 883, 903
  and cul-de-sacs, 736, 865
  custom, fabrication of, 883
  drainage holes in, 736, 865
  early use of, 682, 715
  expandable, 882, 903–906
    fabrication of, 903–905

Conformer—*Continued*
vs. solid conformer, 905–906
and finished prosthesis, 870
following trauma, 863, 870
in grafting, 865, 883
postoperative use of, 730, 732, 736, 737, 870–871
pressure, 839, 840, 874–876, 884
fabrication of, 874–875
retention of, 883
silicone, 882, 883
special surgical, fabrication of, 870
spectacle-mounted, 883–884
Teflon, 882, 883
in treatment of lid burns, 861, 862
trial model, 870–871
fabrication of, 871
Conjunctiva, surgical treatment of
in enucleation, 724, 727–728
in evisceration, 729, 731, 732
Contact lens, 766, 768, 773, 803. *See also* Scleral cosmetic lens
corneal vs. scleral lens, 803
in treatment of lid burns, 861, 862
Contracted socket
congenital
implants for, 881
surgical treatment of, 881, 883, 884
dissection for, 885–886
and enucleation, 879–880
expandable conformer for, 903–906
and migration of implant, 879
and orbital hypoplasia, 879–895
and reconstruction of cul-de-sacs, 885–887
and trauma, 879
Cornea, in evisceration, 685, 729, 730, 732
Corneal cosmetic lens, 773. *See also* Contact lens; Scleral cosmetic lens
opaque, use of, 773
prosthetic, applications of, 773
Corneal cosmetic shell, 770. *See also* Scleral cosmetic shell
Corneal graft, in treatment of lid burns, 861
Corneal injury and scleral cosmetic lens, 766
Corneal opacity, prosthesis for, 773
Corneal ulceration
and lid burns, 860
and scleral cosmetic shell, 769
Cosmetic optics, 741, 743, 772, 783–787, 872
Cosmetic results
and anatomy of eye, 843, 855
camouflage, 782
of cranial-orbital defect repair, 901
and enucleation, 855
and evisceration, 684, 685, 718, 723, 729, 855
with keratectomy, 855
without keratectomy, 730, 732, 855
and impression methods, 748
and prosthesis, 740–741, 743–744, 855
and phthisical globe, 855
Cover shells, 763–764
vs. scleral cosmetic prostheses, 763
Cranial-orbital defects, prosthetic correction of, 897–901
Cul-de-sac
and contracted socket, 885–887
defect of, traumatic, 865
inferior, loss of, 825–833 835–840
causes, 825–826, 829
and chronic irritation, 825–826, 833
and ectropion, 829–831, 838
following enucleation, 825–829
and migration of implant, 829, 837, 840
prosthetic treatment for, 835–840
and retention of prosthesis, 825, 829, 835–840
surgical treatment for, 825–829, 835, 864, 885
preservation of
in enucleation, 725, 825

in treatment of lid burns, 861–862
use of conformer for, 736, 865
and prosthetic fitting, 717, 738, 890
shrunken, and ptosis, 817
and treatment of congenital anophthalmia, 882
Cycloplegics in treatment of lid burns, 859, 861–862

Dacriose, for ophthalmic irrigation, 745
Dacron, use of, with implants, 683, 706, 732, 901
Dental alginate. *See* Alginate, in impression fitting
Diplopia, prosthesis for, 769, 773

Ecblepharon, 713, 714
Ectropion
and enucleation, 831
and extrusion
of implant, 835–837
of prosthesis, 759, 838
following trauma, 859, 862
and loss of cul-de-sac, 829–831
and migration of implant, 847, 848, 852
and ptosis, 817
surgical treatment of
cicatricial, 831–832
and lid burns, 862–863
senile atonic, 829–831
Entropion
and conformers, 905–906
following trauma, 863
and ptosis, 817
Enucleation
and bone growth, 879
and contracted socket, 879–880
and cosmetic results, 855
and ectropion, 831
following trauma, 864–865, 897
history of, 681–686, 689
and lid deformity, 859
and loss of cul-de-sac, 825
and migration of implant, 845, 853
prostheses for, 735–746, 773
and prosthetic motility, 843
and ptosis, 818
simple, 682, 723, 738
and sulcus deformity, 791
surgical technique, 724–725, 727–729, 864–865
and Tenon's capsule, 843
Enuclene, and chronic irritation, 832
Erosion of implant, 691, 845–846, 847
Evaluation of prosthesis, 743–744
Eversion of lid. *See* Ectropion
Evisceration
cosmetic results of, 723, 729, 730, 855
vs. enucleation, 684–686, 723, 729
glass beads used as implant, 709
history of, 684–685
with keratectomy, 685, 729–730, 731
without keratectomy, 685, 730–732
prostheses for, 718, 773, 777, 779
and ptosis, 818
surgical technique, 729–730, 731, 732
and sympathetic ophthalmia, 684, 685, 729
and tumor, 684
Excision, simple, 684–685
Exenterated socket, 891, 892–894
and bone graft, 892, 893
and cartilage, 892, 894
and inorganic materials, 892
prosthetic treatment for, 892
treatment of trauma, 892
External pressure. *See also* Conformer, pressure
in correction of extrusion, 838–839, 840
vs. surgical treatment, 839, 840
Extrusion, 684, 689, 691, 845–846
causes of
conformer, improper use of, 736
ectropion, 838
inadequate closure, 845
infection, 846
loss of cul-de-sac, 825, 835, 840
migration of implant, 847

Extrusion, cause of—*Continued*
pressure necrosis, 747, 752
prosthetic fitting, improper, 845, 846
size of implant, 726, 792, 845, 846
surgical insertion, improper, 845
symblepharon, 838
tissue prolapse, 838
correction of
external pressure, 838–839, 840, 875
surgical, 833, 843–849, 866
and ectropion, 835–837
and evisceration, 685, 691
and integrated implants, 698, 845
and magnetic implant, 702
and reconstruction of orbital floor, 866
and Tenon's capsule, 845

Fascia bulbi. *See* Tenon's capsule
Fascia lata, in sulcus deformity repair, 792–793
Fitting blanks, 800–801
Foreign body reaction and implant, 705–706, 845, 847
Fracture
blowout, of orbital floor, 865–866, 894
of floor and rim, 894
of lateral wall, 894
of medial wall, 894–895
of zygoma, 894

Glass beads
in correction of sulcus deformity, 793
in implantation, 706–707, 846
Glass prostheses. *See also* Prosthesis
reform, history of, 714–716
shell, history of, 713–714, 763
Gold, use of, for implants, 683, 691, 698, 881

Heterochromia of iris, corneal cosmetic lens for, 773

Implant. *See also* Implantation; Implant materials; Prosthesis
and bone graft, 796
for contracted socket, 881
diameter of, 844
extrusion of, 684, 685, 689, 691, 698, 726, 747, 752, 792, 833, 835, 845–846, 847
and foreign body reaction, 705–706, 845, 847
history of, 682–684, 689–709
magnetic, 698, 700, 702, 704–705
metallic-faced, and tissues, 845–846
migration of, 683, 684, 706, 726, 829, 837, 843–849, 851–855, 866, 879
and prosthetic motility, 684, 689, 694, 728–729, 744, 837, 847, 851
size of, and sulcus deformity, 792
types of, 683, 689–709, 725–726
Allen type, 683, 684, 702, 703, 845
buried, 683, 689–691, 845, 864
buried integrated, 698–709
Cutler type, 694, 695, 846
exposed integrated, 691–698
integrated, 683–684, 691–709, 726, 845
Iowa type, 703, 747, 845
Mules sphere, 683, 690, 691, 698, 708, 738
Troutman type, 701, 846
volume of, 844–845
Implantation
complications of, 845–849
defined, 689
Mules technique, 691, 715
and reconstruction of socket, 889
secondary, 706
and surgical closure following enucleation, 727–729
Implant materials, 683, 691–709, 725–726. *See also under specific materials*

acrylate, 689, 691, 694, 698, 702, 703, 726, 732
Dacron, 683, 706, 732, 901
glass, 683, 690, 691, 725–726
gold, 683, 691, 698, 881
polyvinyl sponge, 705, 707, 726
silicone, 683, 685, 706, 708, 726, 732, 897, 899, 901
tantalum, use with, 694, 696, 845–846
tissue tolerance of, 689, 691, 716
Vitallium, 683, 691, 697
Impression fitting techniques
for loss of cul-de-sac, 838
for posttraumatic orbit, 871–872
for prosthesis, 717–718, 737–740, 747–762, 773
full, 738–739
modified, 737–740, 747–762
for sulcus deformity, 800–801
with scars or adhesions, 873–874
for scleral cosmetic shell, 778–779, 873
Impression materials. *See also under specific materials*
for fitting of scleral cosmetic shell, 778
for modified impression fitting of prosthesis, 748–749
in prosthetic correction for loss of cul-de-sac, 838
in prosthetic correction for sulcus deformity, 800
Impression shell, 748–749, 778–779, 871
Impression tray. *See* Impression shell
Infection
and bone graft, 796
chronic persistent, 684
and lid burns, 859
and implants, 698, 845, 846, 866
preoperative, use of antibiotics for, 730
and surgical procedure, 846
Inversion of lid. *See* Entropion
Irideremia, corneal cosmetic lens for, 773
Iris
atrophy of, corneal cosmetic lens for, 773
coloboma of, 765, 768, 773
and cosmetic optics, 784, 785, 786
diameter of, and prosthesis, 742, 781
replicating, for prostheses, 742, 750, 769, 770, 771, 780–781, 782
Iris-cornea piece, 750
Irregular socket, 717, 738, 739, 743–744, 747, 748
Irrigating tube, Houser-Stokes, 861
Irrigation
and prosthesis, 745
in treatment of chemical burns, 861
Irritation
as cause of extrusion, 838
chronic
and loss of cul-de-sac, 825–826, 833
treatment for, 832–833
and prosthesis, 744, 745, 838
Ischemia
as complication in prosthetic fitting, 838, 846
and severity of chemical burns, 861

Keratectomy, 685, 729–730, 731
Keratitis, exposure
prevention of, and lid burns, 860
and ptosis, 803, 804, 812
Keratoplasty, 861

Lagophthalmos and ptosis, 761, 803
Lens, contact. *See* Contact lens
Lens, scleral cosmetic. *See* Scleral cosmetic lens
Levator resection, 761, 803
Lid deformities. *See also under specific lid deformities*
from chemical burns, 859, 860–863
complications, 859, 863–867
cosmetic camouflage, 872
destruction of lid, 864

Lid deformities—*Continued*
distortion, optical correction, 785–786
and posttraumatic orbits, 869–876
from thermal burns, 859–860
from trauma, 859, 863–867
upper lid fold and prosthesis, 744
Lid notching
as complication following trauma, 859
surgical treatment of, 863

Marcus Gunn syndrome, 803–804
Methyl methacrylate
for conformers, 736, 882
curing and finishing of, 744
for implants, 689, 726
for prostheses, 716–717
for prosthetic shelf device, 806
in replicating iris, use of, 742
tissue tolerance of, 689, 716
Microfilm, use of, in molding, 749
Microphthalmia, congenital, 879, 880–883
and degree of hypoplasia, 882–883
expandable conformer for, 903
prosthetic fitting for, 817
prosthetic treatment of, 883
and ptosis, 817
scleral cosmetic lens for, 771, 773, 880
Migration of implant, 683, 684, 706, 845, 847–848, 851–855
and contracted socket, 879
and ectropion, 847, 848, 852
and enucleated socket, 724, 853
and loss of cul-de-sac, 829, 837, 840, 847–848
and prosthetic fitting, 847, 849, 852
and prosthetic motility, 837, 840, 847, 851
prosthetic treatment of, 851–855
and ptosis, 851
removal of implant, 853, 866
and size of implant, 726
surgical treatment of, 843–849, 866
types of, 851–852
Moldite. *See* Alginate, in impression fitting
Motility, prosthetic. *See* Prosthetic motility
Mucoid secretion, control of, 838
Mucotome, Castroviejo type, 826, 865
Mucous membrane graft
and congenital anophthalmia, 883
and extrusion of implant, 833
and lid burns, 861
and loss of cul-de-sac, 826–827, 828, 865
and socket following trauma, 863, 865
use of oral mucosa
and conjunctiva, 867
technique of, 826, 865
Muscles of eye, in enucleation, 725, 727–729
Mustarde's dissection
for absent socket, 887
for contracted socket, 886

Occluder, use of, 869, 875
Oil colors, use of, in replicating iris, 742
Ophthalmoplegia, 804
Optic nerve, surgery of
in enucleation, 724, 725, 829
in evisceration, 730
Orbicularis muscle, and prosthetic fitting, 751, 762
Orbital angulation, and prosthesis, 743–744
Orbital fat, atrophy of, and sulcus deformity, 792
Orbital floor
blowout fractures of, 865–866
reconstruction of, 866, 892–894
Orbital index, 881
Orbit, posttraumatic, 869–876

Palpebral fissure
distortion of, optical correction for, 785–786
and prosthetic fitting, 739, 740,

743, 753–755, 779, 801, 838
and ptosis, 753, 817
narrow
optical correction for, 785
prosthetic correction for, 753–754
size of
and expandable conformer, 903
optical correction for, 783–784, 784–785
width of
optical correction for, 784, 785
prosthetic correction for, 754–755
Photophobia, 766, 768
Phthisical globe
and cosmetic results, 855
enucleation of, 748
prosthesis for, 718, 747–748, 763, 773
and ptosis, 818–820
and superior sulcus deformity, 816
Phthisis bulbi. *See* Phthisical globe
Plexiglass cement, and prosthetic shelf device, 807
Polycoria, cosmetic lens for, 773
Polyvinyl plastic, and repair of exenterated socket, 892
Polyvinyl sponge
in correction of sulcus deformity, 793
for implants, 705, 707, 726
Posttraumatic orbit. *See also* Trauma
with lid deformities, 869–876
and prosthetic motility, 869
Pressure atrophy
conformer for, 884
in socket reconstruction, 884, 886
Pressure pack
construction of, 839
for loss of inferior cul-de-sac, 839, 840
Prosthesis. *See also* Prosthetic fitting; Scleral cosmetic lens; Scleral cosmetic shell; *and under specific topics*
acrylic, 691, 716–717, 744, 762
fabrication of, 762
finishing of, 762
alignment, optical correction for, 786–787
care of, 744–746
correcting over-prominence of, 752–753
correcting recession of, 753
correcting simulated exotropia, 757–758
and exenterated socket, 892
follow-up examinations, 745–746
glass reform
history of, 714–716
and implantation, 715
glass shell, history of, 713–714, 763
plastic, history of, 716–718
and reconstruction of orbital floor, 866
vs. scleral cosmetic lens, 768
Snellen reform, 715, 737, 738
correcting poor retention of, 759
stock fitted reform, 739
temporary, use of, 737, 740, 865, 898
and traumatic socket, 869
Prosthetic fitting, 717–718, 735–746, 752–761, 855. *See also* Prosthesis
cosmetic evaluation of, 740–741
distorted upper lid margin, 758–759
and loss of inferior cul-de-sac, 835, 838, 840
and migration of implant, 847, 849, 852
palpebral fissure in, 753–755
preliminary, 736–737
for ptosis, 760–761, 817–822
and reconstruction of socket, 890–892
for sagging lower lid, 755–756
scleral cosmetic, 766–771, 778, 779–780, 873
for shallow fornix, 759
shapes
plastic, 717, 740

Prosthetic fitting, shapes—*Continued*
prefinished, 740
wax, 740
for sulcus deformity, 799–802, 814, 816–817, 821–822
surgical treatment as aid in, 761
techniques, 717–718, 737–742, 747–762
empirical method, 717–718
full impression, 738–739
impression method, 717–718, 773
modified impression, 737, 738–742, 747–762
for upper lip fold, 756–757
and void behind prosthesis, 742
Prosthetic motility
and anterior surface of implant, 728–729
and buried integrated implants, 698
and cosmetic results, 855
and implants, 683–684, 689
improvement of, in fitting prosthesis, 738
and integrated mesh implants, 694, 726
and magnetic implants, 702
and migration of implant, 837, 847, 851
and posttraumatic socket, 869
and retention of implant, 840
and scleral cosmetic prostheses, 776
use of cul-de-sacs for, 732
Prosthetic selection guide, 773
Prosthetic shelf devices for ptosis, 803–812
case studies, 810–811
cosmetic advantages of, 804
fabrication of, 804–805
fitting of, 806–809
Psychological adjustment to eye loss, 735
Ptosis
causes of, 813, 817, 851
and congenital anophthalmia, 817
and congenital microphthalmia, 817
and cranial-orbital defects, 897
paralytic, surgery for, 803
and phthisical globe, 818–820
prosthetic correction of
cosmetic results, 818–819
fitting techniques, 739, 760–761, 817–822
shelf devices, 803–812
and surgical treatment, 822
and reconstruction of socket, 887, 888
and superior sulcus deformity, 813–814, 821–822
surgical correction of, 791–796
complications, 803–804
Ptosis crutch, 767, 804. *See also* Prosthetic shelf devices for ptosis
Pupil center and scleral cosmetic shell, 780
Pupillary level, prosthetic adjustment of, 741–742

Recession of prosthesis, optical correction for, 784
Reconstruction of orbital floor, plastic plate, 866
Reconstruction of socket, 884–890
and cul-de-sacs, 885, 887, 888, 890
implantation procedures, 889
and prosthetic fitting, 890–892
and ptosis, 887, 888
resection of scar tissue, 889
and skin graft, 884–890
surgical procedures for, 884–892
use of pressure atrophy in, 884, 886
use of skin graft vs. mucosal graft, 884
Retention of conformer, 883–884
Retention of implant, 837, 840. *See also* Extrusion
Retention of prosthesis, 825, 835, 838, 840. *See also* Extrusion
Retraction of implant and superior

sulcus deformity, 792
Retraction of lid, prevention of, 705, 860, 862
Retraction of socket
following enucleation, 683
following evisceration, 689-691
Rotation of scleral cosmetic shell, 779

Sclera, surgery of
in enucleation, 727
in evisceration, 729–730, 732
Scleral cosmetic lens, 718, 763–776, 777
artwork for, 774–776
and atrophied eye, 767
for blind exotropic eye, 820
and coloboma, 768
and corneal injury, 766
evaluation of, 772
fabrication of, 768–770, 771
fitting techniques, 766–771, 873
flush-fitting type, 766, 773, 874
irregularly shaped, for scarred eyes, 873
minimum clearance fluidless type, 766, 773
with optics, 770–772
for phthisical globe, 820
prosthetic applications of, 773
thickness of, 768, 777–778
for traumatic injury, 773, 873
wear cycle during fabrication, 771
Scleral cosmetic prosthesis. *See* Scleral cosmetic lens; Scleral cosmetic shell
Scleral cosmetic shell, 718, 763–776, 777–782
and atrophied eye, 767, 779
and cataract, 765
and coloboma, 765
vs. conventional reform prosthesis, 781–782
disadvantages of, 781–782
and evisceration, 777, 779
fabrication of, 780–781
fitting techniques, 778, 779–780, 873
irregularly shaped, for scarred eyes, 873
and opaque cornea, 769
polishing of, 781
thickness of, 777–778, 780
for traumatic injury, 873
wearing periods of, 782
Scleral evisceration, prosthesis for, 773
Scleral patches, human donor, 846
Shrunken socket. *See* Contracted socket
Silastic. *See* Silicone
Silicone
conformers, 736, 882, 883
in correction of sulcus deformity, 793
and evisceration, 685, 732
implants, 683, 685, 706, 708, 726, 897, 899, 901
lubricants, as tear supplements, 745
and repair of exenterated socket, 892
Simulated exotropia, correction of, 757–758
Simulated hypertropia, 757–758
Skin graft
and congenital anophthalmia, 883
and ectropion, 831–832
and extrusion of implant, 833
and lid burns, 860, 861, 862–863
and loss of cul-de-sac, 827–829
in socket reconstruction, 884–890
vs. mucosal graft, 884
in surgical treatment of lid or socket, 867
Sling operations, 803
Socket, exenterated. *See* Exenterated socket
Socket reconstruction. *See* Reconstruction of socket
Spectacle lens
and prosthesis, 741, 742, 743, 783–787
and scleral cosmetic lens, 772
Spiral of Tilleaux, 845

Steroids, use of
in skin graft, 827
in treatment of lid burns, 859, 861, 862
Stock eye, 716, 736, 739
Stone casting, in fabrication of prosthesis, 740, 749, 762, 779, 874
Strabismus, secondary operation for, 691
Superior rectus paralysis, 804
Superior sulcus deformity
causes of, 791–792, 813, 814–816
prosthetic correction of, 799–802, 813–814, 816–817, 821–822
examination of patient, 799
factors in cosmetic results, 816
factors in fitting, 799, 816
fitting techniques, 800–802, 816–817, 821–822
and surgical treatment, 822
and ptosis, 813–814, 821–822
surgical correction of, 791–796
bone graft, 793–796
cartilage graft, 793
case history, 796
dermal graft, 793
fat graft, 793
orthopedic technique, 794
use of fascia lata, 792–793
use of inorganic materials, 793
Surgical methods
for ectropion, 829–831
for enucleation, 724–725, 727–729
history of, 681–686
for evisceration, 729–732
and keratectomy, 729–730, 731
for exenterated socket, 892–894
in loss of inferior cul-de-sac, 825–829
for ptosis, 792–796
for socket reconstruction, 885–892
for superior sulcus deformity, 792–796
for trauma with lid deformities, 861–867
Symblepharon
as cause of extrusion, 838
following trauma, 826, 859, 862
and treatment for loss of cul-de-sac, 826, 827

Tantalum mesh, in implants, 694, 696
and complications, 845–846
Tarsal plates, modification of, 752, 754–755, 758
Tarsorrhaphy
and lid border destruction, 864
and lid burns, 860, 863
and loss of cul-de-sac, 829
and sulcus deformity, 817
Tear supplements for prosthesis, 745
Teflon
for conformers, 882, 883
and exenterated socket, 892
for reconstruction of orbital floor, 866, 894
Tenon's capsule
anatomy of, restoration, 843
and enucleation, 724, 725, 727–728, 843
and evisceration, 729–730, 732
and implant, 844, 845
extrusion, 845
Thermal burns, 859–860, 861–863
scleral cosmetic prostheses for, 873
treatment of, 859–860, 861–863
preliminary, 859–860
Tissue tolerance
of glass, 691
of gold, 691
of methyl methacrylate, 689, 716
Trauma
blowout fractures of orbital floor, 865–866
and contracted socket, 879
and cranial-orbital defects, 897
and enucleation, 723, 864–865, 889
and exenterated socket, 892
and lid deformities, 859–867, 869–876
complications of, 859, 863–867
prosthetic treatment of, 869–876
surgical treatment of, 863–867

and loss of cul-de-sac, 825, 861–862, 865
and scars or adhesions, prosthetic fitting, 873–874
and scleral cosmetic lens, 773
and sulcus deformity, 791, 792
Traumatic socket, 869. *See also* posttraumatic orbit
Trichiasis, following trauma, 859

Vaseline gauze, in burn treatment, 860
Volume of globe, 844–845
Volume of implant, 844–845

Wax pattern. *See also* Impression fitting techniques
evaluation of, 750–752
modifications of, 752–762
preparation of, 749–750
Wills Eye Hospital and Research Institute, 723

Z-plasty
and loss of cul-de-sac, 826–827
technique of, 826, 827
Zygoma, fracture of, 894